Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Meet the Cure Team Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Cure Symposium Calendar

Second Annual $500,000 XSeed Award Launched by Deerfield Management to Support Underfunded and Underrepresented NYC Life Science Startups

Award recipients will receive a grant to help bridge neurodegeneration translational research to market.

November 03, 2021 10:17 AM Eastern Daylight Time

NEW YORK–(BUSINESS WIRE)–Deerfield Management Company, a New York City-based healthcare investment firm today announced its second annual XSeed Award, a program designed to support New York City early-stage life science, minority-led startups. This year’s XSeed Award will be granted to individuals working on neurodegeneration research development projects.

“Funding translational product development by underrepresented communities is critical to help spark innovation,” said James E. Flynn, Managing Partner at Deerfield. “Broader diversity allows for new and different vantage points to be incorporated into the innovation and startup community, and the varied perspectives indisputably create better ideas and solutions. NYC is one of the most diverse communities in the world, and so must be our early-stage life science community.”

According to Pitchbook, life science ventures led by women and minorities still face a substantial funding gap. Female founders in the U.S. raised only 2.2 percent of total venture capital funding in 2020 and funding to Black and Latinx founders equate to only 2.4% of capital raised from 2015 through August 2020.

The underrepresented scientists and entrepreneurs working on important healthcare projects in NYC are actively furthering discoveries but too often lack support to progress more cures for patients. Through fostering this community of individuals, NYC can help change the disease narrative of the Biotech Industry.

“The New York City Economic Development Corporation is overseeing the City’s $1 billion investment in life sciences, and for us it’s about breaking down barriers and creating equal opportunity in the field. We applaud Deerfield Management for its efforts to support minority-led life science research and early-stage ventures through the second XSeed Award program,” said Rachel Loeb, President and CEO at NYCEDC. “Now, underrepresented scientists and entrepreneurs can apply for much needed funding to help yield the discoveries and cures of tomorrow.”

Each year, the award is launched with a specific focus, selecting five teams that will be awarded a total of up to $500,000. Finalists present their work to a panel which includes: Claire Pomeroy, MD, President and CEO of the Albert and Mary Lasker Foundation; Nancy Thornberry, Founding CEO at Kallyope, Inc.; Elise Wang, Partner at Deerfield; Joseph Pearlberg, Vice President of Scientific Affairs at Deerfield, H.C. Huang, Senior Director, Deerfield Discovery and Development at Deerfield, and Jennifer Laird, VP, Search & Evaluation – Pain & Neurodegeneration at Eli Lilly.

The deadline for submission is January 7, 2022, and the winners will be announced in March. To learn more about the XSeed Award’s applicant eligibility criteria, visit www.xseedaward.com.

“Being recognized as a winner of the XSeed Award means more than just advancing my research and work, it has enriched my learnings and expanded my networking opportunities.” said Chandrabali Ghose-Paul, Founder and CEO of Bioharmony Therapeutics, a winner of the inaugural XSeed Awards in 2021. “Interacting with Deerfield and a group of my fellow recipients strengthens our fight against infectious diseases through knowledge and support.”

“The XSeed Award is what true executive sponsorship looks like,” remarked Ron Mitchell, CEO of Humanity Health, a career acceleration and talent sourcing platform for underrepresented healthcare leaders and entrepreneurs which is supported by Deerfield. “Sponsorship is about amplifying, connecting, endorsing and supporting leaders in their work. All four of those elements are deeply ingrained in this amazing opportunity provided by Deerfield.”

Deerfield created the XSeed Award in tandem with its development of Cure, the life science campus it built in partnership with New York City Economic Development Corporation (NYCEDC). The Cure campus at 345 Park Avenue South in Midtown Manhattan is bringing together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease. Residents have access to move-in-ready laboratory space, engineering and computing space, as well as other amenities and support services.

ABOUT DEERFIELD

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas and technology in bold, collaborative and inclusive ways. For more information, please visit www.deerfield.com.

Contacts
Media Contact:
Caroline Drucker
[email protected]